- UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION
- UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study.
- LUPUZOR™ UPDATE. PK study commencement approved by MHRA – patient dosing to commence imminently
- TR1 – Avion Pharmaceuticals – Major Holdings in Shares (10 January 2022)
- TR1 – Luca Associates – Major Holdings in Shares (4 January 2022)
- TR1 – Lanstead – Major Holding in Shares
- Subscriptions and Placing to raise £3.55 million; Sharing Agreement; to fund Investment in R&D pipeline • Company’s Partner Alora and two longstanding investors including Lanstead to participate at an Issue price of 11p – 80% premium to current share price
- Collaboration with Imperial College London
- CORPORATE UPDATE – The Evolution of ImmuPharma
- EURONEXT DELISTING – Date: 18 October 2021
- Prof. Sylviane Muller awarded prestigious Legion d’honneur.’
- Corporate Update
- INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2021
- Director & PDMR Share Purchases
- Lanstead Capital TR1
- FDA approves the Lupzuor™ PK study
- BOARD CHANGES
- BOARD APPOINTMENT
- 2021 RESULT OF ANNUAL GENERAL MEETING – ALL RESOLUTIONS PASSED
- FDA to agree on the Lupzuor™ PK study via a written response to “Type
- Notice of AGM and posting of Report & Accounts
- Director Retirement
- FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2020
- Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021
- Appointment of Company Secretary
- Lanstead Capital TR1
- ImmuPharma to present at Biotech Showcase™ Digital 2021
- Total Share Capital Notification
- Grant of Share Options & PDMR dealing
- Conversion of Convertible Security
- Conversion of Convertible Security
- FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
- Total Share Capital Notification
- Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
- Total Share Capital Notification Admission to trading on Euronext Growth Brussels of newly issued ordinary shares
- INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2020
- Share Subscription into Incanthera plc (“Incanthera”)
- Repayment of Convertible Security – Lind Global Macro Fund, LP
- Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients
- Conversion of Convertible Security – Lind Global Macro Fund, LP
- Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund
- TR1 – Notification of major interest in shares by Lanstead Capital
- Director/PDMR Shareholding/TR-1
- Placing to raise £6.5 million – update; related party transaction
- Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund
- Placing to raise £6.5 million
- TR1 – Notification of major interest in shares by Lanstead Capital
- Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients
- 2020 Annual General Meeting – all Resolutions Passed
- Total Share Capital Notification
- ImmuPharma PLC (“ImmuPharma” or the “Company”) Director/PDMR Shareholding
- Strategic investments from two specialist US healthcare investors for continued development of ImmuPharma’s therapeutic pipeline
- Notification of Change of Registered Office Address
- Notification of Change of AGM Venue
- Notice of AGM and posting of Report & Accounts
- TR1 – Notification of major interest in shares by Lanstead Capital
- ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka
- Audited Report & Accounts published on website
- FINAL RESULTS For the 12 months ended 31 December 2019
- ImmuPharma to present live on ‘Investor Meet Company’ platform Tuesday 7 April 2020 | 10.30am (BST)
- TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020
- TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020
- Subscription to raise £1.5 million to fund expansion of R&D pipeline
- Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document
- Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market
- ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial
- Admission to trading on Euronext Growth Brussels
- Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels
- Dual listing on Euronext growth Brussels
- Share price volatility
- ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco
- TR1 – Notification of major interest in shareholdings
- ImmuPharma and Avion Pharmaceuticals sign exclusive licence
- INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019
- TR1 – Notification of Major Interest – Lanstead Capital Investors
- TR1 – Notification of Major Shareholding
- 2019 Annual General Meeting – All resolutions passed
- Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”)
- Subscription to raise £2.66 million
- Notice of AGM and posting of Report & Accounts
- FINAL RESULTS ANNOUNCEMENT for the twelve months ended 31 December 2018
- Corporate Update
- Update on Nucant cancer programme
- IMM March 2019 Corporate Update
- Technology review published in Nature Communications
- Appointment of NOMAD
- Update on Corporate Activities
- Nominated Adviser Status
- Interim results announcement for the six months ended 30 June 2018
- Standford Capital Partners and Si Capital are appointed as joint broker
- IMM September 2018 Corporate Update
- 2018 Annual General Meeting – All Resolutions Passed
- ImmuPharma announces positive pre-clinical data on its CIDP programme
- Annual Report and Accounts Posted to Shareholders
- Further Analysis from its Pivotal Phase III Trial of Lupuzor™ in Patients with Systemic Lupus Erythematosus (SLE) Shows Positive Results in the Europe Cohort1
- Holding in company
- Immupharma PLC confident on Lupuzor’s™ future
- Holding in company
- Holding in company
- Top line results of Lupuzor™ Pivotal Phase III Trial
- Appointment of Joint Broker
- Lupuzor™ ‘database lock’ confirmed for 6 April 2018
- London Investor Evening – Monday 26 February 2018 @ 6pm
- Holding in Company
- Notification of Major Interest – Lanstead Increases Holding to over 5%
- Successful Placing to Raise £10 Million
- Completion of Lupuzor™ Pivotal Phase III Study and Initiation of Follow Up Study
- Update on Lupuzor™ Pivotal Phase III Study
- ImmuPharma PLC (“ImmuPharma” or the “Company”) Holding(s) in Company
- Successful Completion of Lanstead Sharing Agreement
- Interim Results Announcement for the six months ended 30 June 2017
- ImmuPharma initiates preparation of Lupuzor’s™ regulatory submissions
- Update on Lupuzor™ Pivotal Phase III Study
- 2017 Annual General Meeting – All Resolutions Passed
- Annual General Meeting and Investor Presentation
- Notice of Annual General Meeting on 30 June 2017 at 10.30am
- Final Results Announcement for the twelve months ended 31 December 2016
- Notification of full year results – 1st June 2017
- Update on Lupuzor™ Pivotal Phase III Study
- Notification of Major Interest by Legal & General
- Successful £4.1 Million Fund Raise Following the Close of the Accelerated Bookbuild
- Accelerated Bookbuild for the Issue of Equity
- Update on Lupuzor™ Pivotal Phase III Study – Full Analysis of Patient Recruitment
- Change of Adviser
- Update on Lupuzor™ Pivotal Phase III Study – Patient Recruitment Completed
- Update on Cancer Compound IPP-204106 ‘Nucant’
- Notification of Major Interest by Legal & General
- TR1 Notification of Major Interest
- Proposed Accelerated Bookbuild for Vendor Placing and Issue of Equity
- Close of Accelerated Bookbuild
- INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2016
- Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting
- ImmuPharma Invited to Open an Additional Site in Mauritius
- ImmuPharma Invited to Open an Additional Site in Mauritius
- Northland Capital Appointed as Joint Broker
- Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller
- First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study
- Notification of Major Interest by Alto Invest to 4.15%
- Notification of Major Interest by Alto Invest
- PRELIMINARY RESULTS
for the year ended 31 December 2015
- Annual Report and Accounts – Notice of Annual General Meeting: 26 May 2016
- Notification of Preliminary Results. Date: 4 May 2016
- First European site opened in France and Patient Recruitment Commences in Lupuzor’s™ Pivotal Phase III Study
- Confirmation of EIS and VCT Qualifying Status and Issue of Equity. £8.4 million total proceeds raised by ImmuPharma within the recent Placing and Subscription
- Result of GM
- First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study
- First US Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study
- Placing and Subscription Raises £8.3 million
- Proposed Placing and Subscription and Notice of General Meeting: 22 February 2016
- Over 70 Lupus Specialists Gather in Paris for Lupuzor’s™ Phase III Investigators Meeting
- Lupuzor™ Pivotal Phase III Trial Recruiting First US Lupus Patients
- Lupuzor™ Phase III Pivotal Trial Update
- Board Change
- Tim McCarthy Appointed as Non-executive Chairman
- Interim Results Announcement for the six months ended 30 June 2015
- Richard Warr
- ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial
- Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™
- Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™
- ANNUAL GENERAL MEETING: 2015
- Notice of Annual General Meeting: 29 May 2015
- Preliminary Results Announcement for the year ended 31 December 2014
- Dr Stéphane Méry Appointed as Non-Executive Director
- Cancer Update: IPP-204106
- Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status
- Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion
- ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France
- AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress
- INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014
- Lupuzor™ Gears Up To Start Pivotal Phase III trials
- ANNUAL GENERAL MEETING: 2014
- ImmuPharma to access pioneering research in the Bordeaux region of France
- New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency
- PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013
- Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014
- Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference
- Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan
- ImmuPharma Sponsors the 2014 European Lupus Conference
- UPDATE: Cancer Programme IPP-204106
- FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities
- Appointment of Scientific Advisory Board
- ImmuPharma secures £50M financing facility for Lupuzor Phase III
- Immupharma gets Lupuzor research boost
- ImmuPharma Commences Trading on the Stuttgart Stock Exchange
- CNRS Confirms Lupuzor’sTM Effectiveness
- ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.
- ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C.
- Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing
- ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012
- ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012
- ImmuPharma PLC Appoints Cenkos Securities as Joint Broker
- PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011
- ImmuPharma PLC Appoints Head of Investor Relations
- ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA
- ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger
Interviews
- 2015: Lupuzor™ founder Professor Sylviane Muller
- Biotech Capital Conference: 6th February 2017
- Chairman Q&A with Tim McCarthy at ImmuPharma PLC (LON:IMM) – April 2018
- Dr Navid Malik, analyst at The Life Sciences Division talks to Directors Talk about the opportunities for Lupuzor™ – Sept 2019
- Dr Navid Malik, Executive director and head of research at the Live Sciences Division who works with Immupharma discusses their recent licence Agreement for Lupuzor with Avion in US – 10 December 2019
- ImmuPharma AGM 2021 – Investor Meet Company Presentation. 28 June 2021
- ImmuPharma chair hails “successful” recruitment for Lupuzor™ trials
- ImmuPharma Chairman details £2.66m financing and open label extension study – July 2019
- ImmuPharma Chairman explains why the Avion deal is so significant – Nov 2019
- ImmuPharma chairman more optimistic on results for its Lupuzor drug – May 2018
- ImmuPharma firmly committed to Lupuzor ahead of managed access programme – 18th Sept 2018
- Immupharma Plc – A multi-billion dollar selling drug
- ImmuPharma PLC Chairman Tim McCarthy Progress, Opportunity, Milestones
- ImmuPharma PLC New Phase III Lupuzor Trial Data Positive – May 2018
- Immupharma Plc On Track, Looking Good and Excited – 18th May 2017
- ImmuPharma plc positive results and new initiation note – May 2019
- Immupharma PLC still confident on Lupuzor’s future – 19th April 2018
- ImmuPharma PLC to open Lupuzor™ trial site in Mauritius
- Immupharma raises £8.3mln for Lupuzor™ trials & early stage pipeline
- ImmuPharma’s CEO, Tim McCarthy, talks to Proactive Investor on commencement of PK study for Lupuzor, on track to deliver results by end Q1, and also plans for progressive news-flow on pipeline over the next period – 8 February 2022
- ImmuPharma’s CEO, Tim McCarthy, talks to Proactive Investor and presents the commercial strategy for the Company’s lupus drug Lupuzor™ as FDA approves PK study in advance to starting the Phase 3 trial – 17th August, 2021
- ImmuPharma’s Chairman Tim McCarthy, and Tim Franklin, Chief Operating Officer join Proactive London’s Katie Pilbeam to explain the latest market update in respect of its late stage Lupus drug, Lupuzor – 10 February 2021
- ImmuPharma’s chairman, Tim McCarthy, talks on widening of portfolio and focus on partnering opportunities – 13 April 2020
- ImmuPharma’s McCarthy on phase III Lupuzor™ trials
- Interview with The Life Sciences Division’s executive director Dr Navid Malik – 5th June 2019
- Interview with Tim McCarthy, Chairman of Immupharma – 19 Jan 2018
- Investigators meeting, December 2015, Paris Lupuzor’s™ pivotal phase III trial
- Life Science Division Executive Director and Head of Research Dr Navid Malik joins DirectorsTalk to discuss ImmuPharma plc – 10 December 2019
- Lupuzor™ could treat a number of diseases, says creator
- Navid Malik, of The Life Sciences Division talks to Proactive Investors on his investment thesis on ImmuPharma and its late stage drug asset, Lupuzor™ as it gears up to start Phase III trials in Lupus patients in H2 2021 – 18 February 2021
- Navid Malik, The Life Sciences Division, talks to Andrew Scott at Proactive about ImmuPharma’s licencing deal with Avion and how it has re-ignited the potential for Lupuzor to be a blockbuster drug – 16 December 2019
- Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update
- Proactive Investors interview with Chairman Tim McCarthy – May 2019
- Q&A with Vadim Alexandre Head of Research at Northland Capital Partners
- Share Talk interview – 3 October 2018
- Successful AstraZeneca lupus study bodes well for ImmuPharma’s Lupuzor™ – Sept 2019
- Tim Franklin, ImmuPharma’s Chief Operating Officer talks to Proactive Investor on the forthcoming meeting in December between the Company’s partner Avion and the FDA, to discuss the international Phase 3 Lupus clinical trial – 25th November 2020
- Tim McCarthy talks to Proactive Investor on 2 February 2018
- Tim McCarthy talks to Proactive Investors – 6th February 2017
- Tim McCarthy updates on Phase III study – 17th May 2017
- Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor following the recent Corporate Update, outlining the broadening of the portfolio and re-emphasising the Board’s focus on delivering near term shareholder value on its key assets including moving Lupuzor into its Phase 3 trial – 22 Nov 2021
- Tim McCarthy, CEO of ImmuPharma, talks to Proactive Investor on the recent Company ‘Corporate Update’, the refocused product development portfolio and the positive corporate structure changes – 4 October 2021
- Tim McCarthy, CEO of ImmuPharma, talks to Proactive Investor on the successful £3.55m fundraising, giving validation of new corporate strategy from Lupuzor™ partner Avion Pharmaceuticals – 20 Dec 2021
- Tim McCarthy, Chairman of ImmuPharma – 17th May 2017
- Tim McCarthy, Chairman of ImmuPharma #IMM – 26th January 2017
- Tim McCarthy, Chairman of ImmuPharma talks to Vox Markets on the deal with US-based Avion Pharmaceuticals, the agreement with Lanstead Capital and what the future holds for ImmuPharma regarding new trial design as well as anticipated upcoming milestones – 13 December 2019
- Tim McCarthy, Chairman of ImmuPharma, provides his first corporate update via the Investor Meet Company platform on 7 April 2020.
- Tim McCarthy, Chairman of ImmuPharma, talks to Proactive Investor about the first significant investment from two US healthcare specialist funds and ongoing news flow – 15 June 2020
- Tim McCarthy, ImmuPharma’s Chairman, talks to Proactive Investors on the transformational Lupuzor™ licensing deal with US Avion Pharmaceuticals
- Vox market audio interview with Immupharma Chairman Tim McCarthy – 19th April 2018
- Vox Markets interview Tim McCarthy, Chairman of ImmuPharma (IMM) – July 2019
- Vox markets interview with Tim McCarthy – Nov 2019
- Vox Markets Podcast – 18th September
- Vox markets podcast – July 2019
- Vox Markets podcast featuring an interview with Dr Navid Malik Executive Director at The Life Sciences Division – Sept 2019
- Vox markets podcast with Tim McCarthy – May 2019
